Mereo BioPharma (MREO) Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – 7, 2022 in Chicago IL.

“We are very pleased that the interim results from our ACTIVATE study have been accepted for presentation at ASCO,” said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. “We are encouraged by the results reported as of the cut off date for the abstract, especially the early efficacy noted in cervical cancer, where we have seen one patient with a complete response, one with a partial response and one with stable disease, as well as the uveal melanoma arm where we saw three patients achieving stable disease with over 20 weeks of treatment. We look forward to sharing the updated data in our ASCO presentation with the oncology community.”

At the time of the February 10, ASCO abstract deadline, of the 27 efficacy-evaluable subjects with minimum of 1 staging scan or radiological/clinical progression, 12 subjects had a clinical benefit with 1 CR, 2 PRs and 9 SDs and 15 subjects had radiological/clinical progression, with an overall response rate (ORR) of 11% and disease control rate (DCR) of 44%. The combination of etigilimab and nivolumab has been safe and well tolerated, with no new safety signals observed to-date.

Details of the data presentation are as follows:

Abstract Title: A Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE)Session Date & Time: Sunday, June 5 at 9AM ET Session Title: Developmental Therapeutics—ImmunotherapyAbstract ID: 2651Poster: 305

You May Also Be Interested In

• Morgan Stanley CEO: investment banking momentum is building - Conference Call
• Toronto-Dominion Bank (TD) Appoints Matt Boss as Head of U.S. Consumer Banking
• Lexaria Bioscience (LEXX) Receives Approval to Begin New GLP-1 Study